888-416-9305 info@abterrabio.com
Abterra Biosciences discovers fully human antibodies from patients

Truly human antibody therapeutics.

Humans mount lasting antibody responses to infectious diseases and cancer. Abterra Bio uses next-generation sequencing, mass spectrometry, and machine learning to comprehensively map the antibody response, and rapidly identify better therapeutic antibodies. We’ve built an interdisciplinary team of data scientists and biologists to re-imagine how antibody therapeutics are developed.

Abterra Bio technology is built on decades of experience in antibody sequencing and analysis. Click on the services below to see how we can help you!

Abterra Bio Reptor Hybridoma Sequencing


Next-Gen Sequencing Hybridoma

Abterra Bio Reptor Bulk B Cell Sequencing


Next-Gen Sequencing Bulk B Cells
Abterra Bio Reptor Hit Expansion


Next-Gen Sequencing Hit Expansion 
Abterra Bio Reptor Library Sequencing


Next-Gen Sequencing Display Library
Abterra Bio Alicanto Rabbit Antibody Discovery


Rabbit Monoclonal Antibody Discovery
Abterra Bio Alicanto Single Domain Antibody Discovery


Single Domain (VHH) Antibody Discovery

Abterra Bio Alicanto Human Antibody Discovery


Human Antibody Discovery
Abterra Bio Valens Sequence Confirmation


Protein Sequence Confirmation
Abterra Bio Valens Antibody Protein Sequencing


Antibody Protein Sequencing

Our partners’ success means everything to us

I have had great experiences using Abterra Bio’s Reptor platform. The data generated was highly valuable, and the team provided quick and open communication throughout the whole process.

Sandeep Kumar, PhD

Associate Director - Antibody Discovery & Engineering, Scholar Rock

I would strongly recommend the services, Valens and Reptor, from Abterra Bio.  Not only were the individuals extremely helpful throughout the development of my project, but they were always available to answer any questions I had throughout the project.  Best of all, Abterra provided high-quality sequences with a rapid turnover which allowed my lab to continue our research with little delay.

Matthew Burchill, PhD

Assistant Professor, University of Colorado - Anschutz Medical Campus

Latest News

PEGS Boston Summit 2021 Presentation

Abstract: Next-generation sequencing of antibody repertoires has provided new insights into natural immune responses.  The correlation between the B-cell receptor repertoire and the serological antibody repertoire has only been analyzed in a small number of studies. ...

Abterra Bio Seattle Angel Conference Winner

We’re excited to announce that Abterra Bio has been chosen as the Winner of the 19th Seattle Angel Conference and the Audience Favorite Award. This year, there were 81 start-up companies from all over the US that had applied. The selection process took around 2-3...

Digital Proteomics is Abterra Biosciences

We're excited to announce that Digital Proteomics is now Abterra Biosciences. Our vision for the business has evolved and it's time to realign our name with our capabilities; we have developed core technologies that are driving our partners' antibody discovery...

We are a CONNECT Cool Company 2021!

We’re excited to announce that Abterra Biosciences has been selected as "A Cool Company" for the second year in a row by CONNECT. CONNECT, a premier innovation company accelerator in San Diego that creates and scales great companies in the technology and life sciences...

Scientific Updates

Why Sequence My Antibody Protein?

Over the past decade of sequencing thousands of antibodies, we've discovered the top reasons to sequence your antibody protein.Top reasons to sequence my antibody  1. To protect my intellectual property through patents for regulatory application and antibody...

Customer Spotlight: Dr. Matthew Burchill

Valens™ Rescues Antibody for Liver Disease ResearchDr. Matthew Burchill explains how Abterra Bio's technology, Valens  rescued his antibody and enabled him to continue his research in chronic liver disease. "The sequencing provided is instrumental to our work as the...

Social Media Posts

Have you lost the #hybridoma for an important antibody? Dr. Burchill from the Univ of Colorado knows the feeling. Read more about how we used Valens to rescue an antibody used in his chronic liver disease research. #antibody #antibodysequencing


Why you should pick NGS over Sanger for your hybridoma sequencing? At Abterra Bio, we use NGS for our high-throughput hybridoma sequencing workflow to save you time and money!
Read about the key differences between NGS vs Sanger here: https://abterrabio.com/hybridoma-sequencing-resources/
#hybridoma #NGS

Load More

Every day, we strive to help our partners and collaborators push the boundaries of their science.

Subscribe To Our Newsletter!

Don't miss out on the latest case studies, posters, and other news.

You have Successfully Subscribed!